|
시장보고서
상품코드
2049518
소화기 치료제 시장 보고서 : 종류별, 투여 경로별, 용도별, 유통 채널별, 지역별(2026-2034년)Gastrointestinal Therapeutics Market Report by Type, Route of Administration, Application, Distribution Channel, and Region 2026-2034 |
||||||
세계의 소화기 치료제 시장 규모는 2025년에 506억 달러에 달했습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 4.06%를 기록하며 2034년까지 732억 달러에 달할 것으로 예측하고 있습니다.
위장(GI) 증후군은 소화관 장기의 기능에 영향을 미치는 의학적 질환을 말합니다. 위, 췌장, 소장, 대장, 담낭, 간 등에 영향을 미치며 보통 소화불량, 속쓰림, 변비, 복부 팽만감 등의 증상이 나타납니다. 일반적으로 사용되는 GI 치료법에는 제산제, 완하제, 지사제, 지사제, 구토제, 항궤양제 등의 처방약과 일반의약품(OTC), 내시경 검사, 방사선 검사, 혈액 검사 등이 있습니다. 이러한 치료법은 질병의 발견을 돕고, 음식물의 영양소 흡수를 촉진하여 소화를 개선하고, 소화기 계통의 수분 흐름을 조절하며, 위산 분비를 최소화하는 역할을 합니다.
염증성 장질환(IBD) 및 궤양성 대장염과 같은 소화기 질환의 유병률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 생활습관의 변화와 건강에 해로운 식습관으로 인해 전 세계 환자들의 질병 재발 위험이 증가하고 있습니다. 또한, 이러한 질병에 걸리기 쉬운 고령 인구의 증가도 시장 성장을 촉진하고 있습니다. 질병 치료를 위한 혁신적인 바이오시밀러 및 세포 치료제 개발 등 다양한 기술 발전도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이러한 생물학적 제제는 정맥주사나 피하주사로 투여되며, 표적치료에 맞게 개별화되어 있습니다. 이 외에도 일반 대중의 건강 인식 증가, 광범위한 연구개발(R&D) 활동, 특히 개발도상국의 헬스케어 인프라의 현저한 개선 등이 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 지금까지 세계 소화기 치료제 시장은 어떻게 성장해 왔으며, 향후 몇 년 동안은 어떻게 성장할 것으로 전망하는가?
- COVID-19는 세계 소화기 치료제 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 시장 유형별 시장 분석은 어떠한가?
- 투여 경로별 시장 현황은 어떠한가?
- 용도별 시장 현황은 어떠한가?
- 유통 채널별 시장 현황은 어떠한가?
- 이 산업의 밸류체인에서 각 단계는 무엇인가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 위장약 시장의 구조는 무엇이며, 주요 플레이어는 누구인가?
- 이 업계의 경쟁은 얼마나 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 소화기 치료제 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 용도별
제9장 시장 내역 : 유통 채널별
제10장 시장 내역 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSM 26.06.10The global gastrointestinal therapeutics market size reached USD 50.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 73.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.06% during 2026-2034.
Gastrointestinal (GI) syndrome refers to a medical ailment that affects the functioning of organs in the digestive tract. It impacts the stomach, pancreas, small and large intestines, gall bladder and liver and is usually characterized by indigestion, heartburn, constipation and bloating. Some of the commonly used GI therapeutics include prescription and over-the-counter (OTC) drugs, such as antacids , laxatives, antidiarrheal agents, antiemetics, antiulcer agents, and endoscopic and radiological procedures and hematological tests. These therapeutics assist in the detection of the disorder and absorbing nutrients from the food to improve digestion, regulate water flow in the GI system and minimize gastric acidity.
The increasing prevalence of GI diseases, such as inflammatory bowel disease (IBD) and ulcerative colitis , is one of the key factors driving the growth of the market. Due to changing lifestyle patterns and unhealthy dietary habits, there is an increased probability of disease recurrence among patients across the globe. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Various technological advancements, such as the development of innovative biosimilars and cellular therapies for the treatment of the disorder, are acting as other growth-inducing factors. These biologics are administered through intravenous and subcutaneous injections and are personalized for targeted treatments. Other factors, including rising health consciousness among the masses, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, especially in developing economies, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Type:
- Branded
- Generic
Breakup by Route of Administration:
- Oral
- Intravenous
- Others
Breakup by Application:
- Ulcerative Colitis
- Crohn's Disease
- GERD
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceuticals.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global gastrointestinal therapeutics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global gastrointestinal therapeutics market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global gastrointestinal therapeutics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Gastrointestinal Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Branded
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Generic
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Application
- 8.1 Ulcerative Colitis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Crohn's Disease
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 GERD
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 AbbVie Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca Plc
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Bausch Health Companies Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Bayer Aktiengesellschaft
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 GlaxoSmithKline Plc
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Janssen Biotech Inc. (Johnson & Johnson)
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Novo Nordisk A/S
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Takeda Pharmaceuticals
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.1 Abbott Laboratories
